Obesity or Overweight study: Maridebart Cafraglutide
Official title Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
ClinicalTrials.gov ID: NCT07575399
What this study is testing
What is Maridebart Cafraglutide?
An investigational injectable medicine being studied as a potential treatment for obesity or overweight. It is designed to activate GLP-1 receptors, which may help reduce appetite and food intake.
Also referred to as AMG 133.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out whether changing from a GLP‑1 receptor agonist to maridebart cafraglutide is effective, safe, and well tolerated in adults with obesity or overweight.
- Who it's for
- Adults who are obese or overweight and are currently using a GLP‑1 receptor agonist.
- What's involved
- Participants will stop their current GLP‑1 drug and start maridebart cafraglutide, with follow‑up visits and safety tests.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Body Mass Index (BMI) ≥ 25 at screening.
- Weight loss of ≥ 10% on weekly GLP-1 RA.
- Stable body weight.
- Stable dose of GLP-1RA.
- Stable gastrointestinal (GI) side effects.
You likely can't join if
- Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
- Previous or planned surgical, endoscopic or device-based treatment for obesity.
- History of malignancy.
- Type 1/Type 2 diabetes mellitus (DM).
- Family or personal history of medullary thyroid cancer.
- Previous participation in a Maridebart Cafraglutide trial.
See the full eligibility criteria
- Body Mass Index (BMI) ≥ 25 at screening.
- Weight loss of ≥ 10% on weekly GLP-1 RA.
- Stable body weight.
- Stable dose of GLP-1RA.
- Stable gastrointestinal (GI) side effects.
- Contraception for females.
- Willingness to follow trial procedures for the duration of the trial.
- Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
- Previous or planned surgical, endoscopic or device-based treatment for obesity.
- History of malignancy.
- Type 1/Type 2 diabetes mellitus (DM).
- Family or personal history of medullary thyroid cancer.
- Previous participation in a Maridebart Cafraglutide trial.
The study team makes the final eligibility decision.
Where it is enrolling
- Pelham, Alabama, United States
- Chandler, Arizona, United States
- Sun City, Arizona, United States
- Sun City West, Arizona, United States
- Chula Vista, California, United States
- Palm Springs, California, United States
- Rialto, California, United States
- San Diego, California, United States
- Santa Ana, California, United States
- Gainesville, Florida, United States
- Hialeah, Florida, United States
- Margate, Florida, United States
- Miami, Florida, United States
- Mt. Dora, Florida, United States
- Orlando, Florida, United States
- Port Orange, Florida, United States
- The Villages, Florida, United States
- Canton, Georgia, United States
- Johns Creek, Georgia, United States
- Union City, Georgia, United States
+ 31 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Pelham, Alabama, United States; Chandler, Arizona, United States; Sun City, Arizona, United States; Sun City West, Arizona, United States; Chula Vista, California, United States; Palm Springs, California, United States and 45 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.